- Home
- PMVP
as 12-17-2024 4:00pm EST
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | PRINCETON |
| Market Cap: | 85.5M | IPO Year: | 2020 |
| Target Price: | $5.75 | AVG Volume (30 days): | 196.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.40 - $3.47 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest PMV Pharmaceuticals Inc. News
PMVP Breaking Stock News: Dive into PMVP Ticker-Specific Updates for Smart Investing
Simply Wall St.
15 days ago
Discover 3 US Penny Stocks With Market Caps Over $40M
MT Newswires
a month ago
PMV Pharmaceuticals Files $200 Million Mixed-Shelf Offering
GlobeNewswire
a month ago
PMV Pharmaceuticals Reports Third Quarter 2024 Financial Results
Simply Wall St.
2 months ago
US Penny Stocks To Consider In October 2024
GlobeNewswire
2 months ago
PMV Pharmaceuticals Provides a Progress Update on PYNNACLE Clinical Trial
Simply Wall St.
3 months ago
PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Good Position To Deliver On Growth Plans
GlobeNewswire
4 months ago
PMV Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Progress Update on PYNNACLE Clinical Trial
GlobeNewswire
6 months ago
Enhancing the Power of PTZs: Canon Announces New PTZ Firmware Updates Lending Greater Control and Operability, Including an Auto-Tracking Lite Version on Compatible PTZ Models*
Compare PMVP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PMVP PMV Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.